Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01148459
First received: June 17, 2010
Last updated: October 16, 2014
Last verified: October 2013

June 17, 2010
October 16, 2014
July 2010
May 2013   (final data collection date for primary outcome measure)
Occurrence of SAEs [ Time Frame: From the time of first vaccination until 14 months post Dose 1 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01148459 on ClinicalTrials.gov Archive Site
  • Occurrence of solicited general and local reactions [ Time Frame: After each vaccine administration over a 7 day follow-up period (day of vaccination and 6 subsequent days) ] [ Designated as safety issue: No ]
  • Occurrence of unsolicited symptoms [ Time Frame: After each vaccine administration over a 30 day follow-up period (day of vaccination and 29 subsequent days) ] [ Designated as safety issue: No ]
  • Occurrence of non-malaria related SAEs [ Time Frame: From the time of first vaccination until 14 months post Dose 1 ] [ Designated as safety issue: No ]
  • Anti-CS antibody titers [ Time Frame: Prior to vaccination and one month post Dose 3 ] [ Designated as safety issue: No ]
  • Anti-HBs antibody titers [ Time Frame: Prior to vaccination and one month post Dose 3 ] [ Designated as safety issue: No ]
  • Anti-CS antibody titers [ Time Frame: 12 months post Dose 3 ] [ Designated as safety issue: No ]
  • Anti-HBs antibody titers [ Time Frame: 12 months post Dose 3 ] [ Designated as safety issue: No ]
  • Occurrence of malaria disease according to specific case definitions [ Time Frame: From Day 0 to Day 420 ] [ Designated as safety issue: No ]
  • Asexual P. falciparum parasitemia prevalence and density [ Time Frame: 12 months post Dose 3 ] [ Designated as safety issue: No ]
  • HIV viral load [ Time Frame: At baseline and at one month, 6 months and 12 months post Dose 3 ] [ Designated as safety issue: No ]
  • Rate of positive CD4 and absolute cell counts [ Time Frame: At baseline and at one month, 6 months and 12 months post Dose 3 ] [ Designated as safety issue: No ]
  • WHO HIV clinical classification progression [ Time Frame: At baseline, one month, 6 months and 12 months post Dose3 ] [ Designated as safety issue: No ]
  • Growth parameters: weight, age/length and middle upper arm circumference for age score [ Time Frame: At Day 0 and Day 420 ] [ Designated as safety issue: No ]
  • Occurrence of solicited general and local reactions [ Time Frame: After each vaccine administration over a 7 day follow-up period (day of vaccination and 6 subsequent days) ] [ Designated as safety issue: No ]
  • Occurrence of unsolicited symptoms [ Time Frame: After each vaccine administration over a 30 day follow-up period (day of vaccination and 29 subsequent days) ] [ Designated as safety issue: No ]
  • Occurrence of non-malaria related SAEs [ Time Frame: From the time of first vaccination until 14 months post Dose 1 ] [ Designated as safety issue: No ]
  • Anti-CS antibody titers [ Time Frame: Prior to vaccination and one month post Dose 3 ] [ Designated as safety issue: No ]
  • Anti-HBs antibody titers [ Time Frame: Prior to vaccination and one month post Dose 3 ] [ Designated as safety issue: No ]
  • Anti-CS antibody titers [ Time Frame: 12 months post Dose 3 ] [ Designated as safety issue: No ]
  • Anti-HBs antibody titers [ Time Frame: 12 months post Dose 3 ] [ Designated as safety issue: No ]
  • Occurrence of malaria disease according to specific case definitions [ Time Frame: From Day 0 to Day 420 ] [ Designated as safety issue: No ]
  • Asexual P. falciparum parasitemia prevalence and density [ Time Frame: 12 months post Dose 3 ] [ Designated as safety issue: No ]
  • HIV viral load [ Time Frame: At baseline and at one month, 6 months and 12 months post Dose 3 ] [ Designated as safety issue: No ]
  • Rate of positive CD4 and absolute cell counts [ Time Frame: At baseline and at one month, 6 months and 12 months post Dose 3 ] [ Designated as safety issue: No ]
  • WHO HIV clinical classification progression [ Time Frame: At baseline, one month, 6 months and 12 months post Dose3 ] [ Designated as safety issue: No ]
  • Growth parameters: weight, age/length and middle upper arm circumference for age score [ Time Frame: At Day 0 and 420 ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children
Safety and Immunogenicity Study of GSK Biologicals' Plasmodium Falciparum Malaria Vaccine 257049 Administered to HIV Infected Infants and Children

The purpose of this study is to assess the safety and immunogenicity of the candidate malaria vaccine in HIV-infected infants and children

This protocol posting has been updated due to protocol Amendment 2.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Malaria
  • Biological: GSK Biological's Investigational Malaria Vaccine 257049
    All infants enrolled to group A will receive 3 doses of the experimental vaccine. The vaccine will be administered intramuscularly.
  • Biological: Human Diploid Cell Vaccine (HDCV) or Purified Vero Cell Rabies Vaccine (PVRV, Verorab) (Aventis Pasteur);

    To ensure consistent vaccine availability, three cell culture rabies vaccines from two manufacturers may be sourced for this trial (Aventis-Pasteur and Novartis). It will be ensured that an individual child will receive all 3 doses of cell culture rabies vaccine from the same product.

    The vaccine will be administered intramuscularly

  • Biological: Purified Chick Embryo Cell Culture (PCEC) Rabies Vaccine (Rabipur or equivalent) (Novartis).

    To ensure consistent vaccine availability, three cell culture rabies vaccines from two manufacturers may be sourced for this trial (Aventis-Pasteur and Novartis). It will be ensured that an individual child will receive all 3 doses of cell culture rabies vaccine from the same product.

    The vaccine will be administered intramuscularly.

  • Experimental: Group A
    Infants enrolled to this group will receive 3 doses of the experimental vaccine.
    Intervention: Biological: GSK Biological's Investigational Malaria Vaccine 257049
  • Active Comparator: Group B
    Infants enrolled to this group will receive 3 doses of the rabies comparator vaccine.
    Interventions:
    • Biological: Human Diploid Cell Vaccine (HDCV) or Purified Vero Cell Rabies Vaccine (PVRV, Verorab) (Aventis Pasteur);
    • Biological: Purified Chick Embryo Cell Culture (PCEC) Rabies Vaccine (Rabipur or equivalent) (Novartis).
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
200
May 2013
May 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

All subjects must satisfy ALL the following criteria at study entry:

  • A male or female infant or child between and including 6 weeks to 17 months of age, at the time of first vaccination.
  • Signed or thumb-printed informed consent obtained from the parent(s)/LAR(s) of the infant or child. Where parents/LARs are illiterate, the consent form will be countersigned by a witness.
  • Subjects who the investigator believes that their parents/LARs can and will comply with the requirements of the protocol should be enrolled in the study.
  • Subjects who are known to be HIV-infected (documented positive DNA PCR), whether taking HIV antiretroviral treatment (ART) or not.
  • Subjects who are born following a normal gestation period.

Exclusion Criteria:

The following criteria should be checked at the time of study entry. If ANY exclusion criterion applies, the subject must not be included in the study:

  • Acute disease at the time of enrolment. However, the presence of an illness listed as Grade I or Grade II (WHO pediatric AIDS clinical staging) will not of itself constitute an exclusion criterion. Enrolment should be deferred if axillary temperature is >=37.5°C.
  • Grade III or Grade IV abnormality on screening laboratory blood sample.
  • Grade III or IV AIDS at the time of enrolment (WHO pediatric AIDS clinical staging).
  • Major congenital defects.
  • Planned administration/administration of a vaccine not foreseen by the study protocol prior to or within 7 days of study vaccine.
  • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine 30 days preceding Dose°1 of study vaccine, or planned use during the study period.
  • Previous participation in any other malaria vaccine trial.
  • Simultaneous participation in another clinical trial including administration of experimental treatment.
  • Same sex twins.
  • History of allergic reactions (significant IgE-mediated events) or anaphylaxis to previous immunizations.
  • History of allergic disease or reactions likely to be exacerbated by any component of the study vaccine.
  • Child in care.
Both
6 Weeks to 17 Months
No
Contact information is only displayed when the study is recruiting subjects
Kenya
 
NCT01148459
112745
Not Provided
GlaxoSmithKline
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP